Welcome to our dedicated page for Medtronic news (Ticker: MDT), a resource for investors and traders seeking the latest updates and insights on Medtronic stock.
Medtronic plc (NYSE: MDT) is a Galway, Ireland-based healthcare technology company whose news flow reflects its broad activity in medical devices, diabetes technology, surgical robotics, and cardiovascular therapies. Company announcements frequently highlight regulatory milestones, clinical evidence, product launches, capital markets activity, and corporate governance developments that matter to investors and healthcare professionals following MDT stock.
Recent news has featured U.S. Food and Drug Administration clearances for key technologies, including the Hugo robotic-assisted surgery (RAS) system for urologic procedures and the MiniMed Go Smart Multiple Daily Injection (MDI) system, which connects the InPen smart insulin pen and the Instinct sensor made by Abbott through the MiniMed Go app. Medtronic has also reported on the broad U.S. commercial launch of the MiniMed 780G automated insulin delivery system integrated with the Instinct sensor, expanding its diabetes technology ecosystem.
Investors can also track Medtronic’s cardiovascular and hypertension-related developments, such as the final National Coverage Determination from the U.S. Centers for Medicare & Medicaid Services for the Symplicity Spyral renal denervation system, and updates on growth drivers like pulsed field ablation and other cardiovascular therapies discussed in earnings releases. Financial news includes quarterly earnings reports, guidance updates, dividend declarations, and details of senior notes offerings and redemptions.
This MDT news page aggregates coverage of topics including diabetes business developments (such as the planned MiniMed IPO registration), conference presentations, leadership and board changes, and major clinical or reimbursement milestones. Readers interested in Medtronic’s role in chronic disease management, minimally invasive surgery, and global healthcare technology can use this page to follow ongoing announcements and review the company’s evolving strategic priorities over time.
Medtronic plc (NYSE: MDT) announced the expansion of its minimally invasive spine surgery ecosystem with new technologies, making it the only provider to integrate spinal implants, biologics, navigation, robotics, and AI data into surgery solutions. Key innovations include the Catalyft™ Expandable Interbody System, Space-D™ Access System, and Accelerate™ Graft Delivery System. These advancements aim to enhance surgical efficiency and patient outcomes, reducing complications and recovery time. With 450,000 spinal fusion procedures annually in the U.S., Medtronic is positioned to set new standards in spine care.
Medtronic plc (NYSE:MDT) has received CE Mark approval for its radial artery access portfolio, including the innovative Rist™ 079 Radial Access Guide Catheter and Rist™ Radial Access Selective Catheter. This marks a significant advancement in neurovascular procedures, offering enhanced navigability and stability through radial artery access. The device has already shown strong customer feedback from over 100 cases in the U.S. The company aims to improve patient outcomes and reduce care costs with this approval, reinforcing its commitment to innovation in medical technology.
On September 17, 2021, Medtronic and Apollo Hospitals performed the first robotic-assisted prostatectomy using the Hugo™ system in the Asia-Pacific region at Apollo Hospitals, Chennai, India. This milestone signifies a shift towards minimally invasive surgery, which may reduce complications and hospital stays. Medtronic's Hugo RAS system aims to enhance access to robotic surgery, addressing historical cost barriers. The system is designed for various soft-tissue procedures and is currently pending regulatory approvals in specific regions.
On September 22, 2021, Medtronic (NYSE:MDT) announced that the U.S. Patent Trial and Appeal Board has affirmed all claims in seven patents related to its InterStim™ sacral neuromodulation devices, dismissing challenges from Axonics. The affirmed patents include U.S. Patent Nos. 8,457,758, 8,738,148, and aspects of 9,821,112. Medtronic plans to resume its IP infringement case in California, seeking to protect its proprietary technology. These patents ensure that Medtronic's innovations remain protected as they expire in 2024 and 2025.
Medtronic has initiated the BRAIVE™ IDE study, enrolling its first patient for the Braive™ growth modulation system aimed at treating Adolescent Idiopathic Scoliosis (AIS). Conducted across the U.S., Canada, and the UK, this clinical trial will assess the device's safety and effectiveness. The Braive system aims to correct spinal curvature while allowing continued growth, addressing a significant pediatric need in scoliosis treatment. The study reaffirms Medtronic's commitment to innovation in pediatric spine care, as approximately 4% of children are affected by scoliosis globally.
On September 13, 2021, Medtronic plc (NYSE:MDT) announced it secured three victories in an intellectual property dispute against Axonics. The U.S. Patent and Trademark Office's Patent Trial and Appeal Board upheld Medtronic's patents related to its InterStim™ systems, which are crucial for sacral neuromodulation technology. This follows a previous affirmation of another key patent in September 2020. Medtronic plans to resume its infringement lawsuit against Axonics once the remaining patent reviews are concluded.
Medtronic plc (NYSE: MDT) has launched a pilot program with Mpirik, aimed at addressing disparities in care for sudden cardiac arrest (SCA). This collaboration seeks to identify high-risk patients through Mpirik's AI platform, Cardiac Intelligence®, by screening electronic health records at five hospitals.
The program aims to tackle treatment disparities affecting women and men of color, who receive implantable cardioverter defibrillators (ICDs) at lower rates than white men. Through this initiative, Medtronic aims to enhance patient care and reduce inequalities in treatment.
Medtronic (NYSE:MDT), a leader in medical technology, will participate in several virtual investor conferences. Key events include the Wells Fargo Healthcare Conference on September 9, featuring Bob White at 10:40 am EDT; the Morgan Stanley Global Healthcare Conference on September 14 with Geoff Martha at 10:15 am EDT; and the BofA Global Healthcare Conference on September 17 at 12:35 pm EDT, with Rob ten Hoedt. Live webcasts will be available, with archived recordings later. Medtronic aims to enhance global healthcare solutions.
Medtronic plc (NYSE:MDT) released promising results from the NAVABLATE study, presented at the European Respiratory Society International Congress 2021, demonstrating the safety and efficacy of bronchoscopic microwave ablation for malignant lung nodules. The study involved 30 patients from the UK and Hong Kong, achieving 100% technical success with only a 3.3% adverse event rate. This method offers a new treatment option for patients ineligible for surgery or stereotactic body radiation therapy. The Emprint Ablation Catheter Kit has received Breakthrough Device Designation from the FDA.
BetterInvesting Magazine has designated Medtronic PLC (NYSE: MDT) as its 'Stock to Study' and D.R. Horton Inc. (NYSE: DHI) as its 'Undervalued Stock' for the November 2021 issue. This announcement underscores the importance of self-guided investment education, especially in light of recent Social Security discussions. CEO Ken Zendel emphasizes the need for individuals to take charge of their financial futures. The selections aim to assist investors in making informed decisions. More information can be found through BetterInvesting's online tools.
FAQ
What is the current stock price of Medtronic (MDT)?
What is the market cap of Medtronic (MDT)?
